Byron Vaughn, MD, MS

Associate Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition

Byron Vaughn

Contact Info

Mailing Address:
420 Delaware Street, SE
MMC 36
Minneapolis, MN 55455

Administrative Assistant Name
GI Division

Administrative Phone

Administrative Email

Administrative Fax Number

Additional Locations

Associate Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition


Medical School, Drexel University, Philadelphia, PA

Residency, Beth-Israel Deaconess Medical Center, Boston, MA

Fellowship, Beth-Israel Deaconess Medical Center, Boston, MA

Master of Science, University of Minnesota, Minneapolis, MN


Dr. Vaughn completed his Internal Medicine residency and Gastroenterology fellowship at Beth-Israel Deaconess Medical Center in Boston. There he developed both clinical and research interests in Inflammatory Bowel Disease. He worked with the IBD Center at BIDMC to study the effect of therapeutic manipulation of the microbiome in Crohn's disease as well as optimizing the management of anti-TNF medications. In addition to his research interests he has worked closely with the medical school teaching students and mentoring physicians in training in clinical and quality improvement research. His main clinical interests include Crohn's disease, Ulcerative Colitis as well as Microscopic colitis and Celiac disease. He also sees patients with recurrent C. difficile colitis. His active areas of research involve clinical trials for IBD.

Awards & Recognition

  • Educational Excellence, University of Minnesota (2020)
  • Clinical Excellence, University of Minnesota (2019)
  • Mpls. St.Paul Magazine "Top Doctor - Rising Star" (2017, 2018, 2019)
  • Minnesota Monthly Magazine “Top Doctors” (2017, 2021)
  • Teacher of the Year, University of Minnesota Gastroenterology Fellowship (2017)
  • 50 Most Influential Volunteers, Crohn’s & ColitisFoundation,  Minnesota/Dakotas Chapter (2017)

Professional Associations

  • Member, American College of Gastroenterology
  • Member, American Gastroenterological Association
  • Member, AGA Academy of Educators
  • Member, Crohn's and Colitis Foundation


Research Summary/Interests

Dr. Vaughn is actively involved in both clinical and translational research for patient with IBD. The intestinal microbiota has recently been identified as a critical component of many intestinal pathways including immune tolerance and inflammation. Dr. Vaughn is working in collaboration with Dr. Alexander Khoruts to continue to understand how the microbiota functions to induce inflammation or tolerance. Additionally, Dr. Vaughn has been a strong proponent for therapeutic drug monitoring. This includes monitoring drug levels for patient on anti-TNFs such as infliximab and adalimumab. His research demonstrates that by close monitoring of these medication and titration to a therapeutic window, patients have more effective disease control and less chance of developing anti-drug antibodies.

He continues to study the effect of therapeutic drug monitoring on antibody development.


  • Jasurda JS, McCabe RP, Vaughn BP. Adalimumab Concentration Changes Following Dose Escalation in Inflammatory Bowel Disease. Ther Drug Monit. 2020 Dec 17;Publish Ahead of Print. doi: 10.1097/FTD.0000000000000849. Epub ahead of print. PMID: 33346627.
  • Aby ES, Lake JR, Vaughn BP. The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes. Clin Liver Dis (Hoboken). 2020 Dec 10;16(5):212-217. doi: 10.1002/cld.1005. PMID: 33318791; PMCID: PMC7727846.
  • Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, Gheysens K, Papamichael K, Osterman MT, Cheifetz AS, Cross RK. Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. J Clin Med. 2020 Sep 28;9(10):3142. doi: 10.3390/jcm9103142. PMID: 32998473; PMCID: PMC7601452.
  • Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2020 Jan 1;26(1):103-111. doi: 10.1093/ibd/izz113. PMID: 31184366; PMCID: PMC6905301.
  • Rajasingham R, Enns EA, Khoruts A, Vaughn BP. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. Clin Infect Dis. 2020 Feb 14;70(5):754-762. doi: 10.1093/cid/ciz318. PMID: 31001619; PMCID: PMC7319265.



Gastroenterology Clinic;University of Minnesota Medical Center

Board Certifications

  • Internal Medicine
  • Gastroenterology

Clinical Interests

Inflammatory Bowel Disease; Clinical trials in IBD; Crohn's Disease; Ulcerative Colitis; Microscopic colitis